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ABSTRACT
Gastroenteropancreatic neuroendocrine tumours (GEP NET) belong to a heterogeneous group of rare tu-
mours. Most NETs of the gastrointestinal tract are non-functioning and therefore are diagnosed at an advanced 
stage, which impedes radical surgery. Overexpression of somatostatin receptors (SSTR) can be found in most 
GEP-NETs.
Somatostatin analogues play a major role in therapy of hormonally active NETs. These agents also have an 
anti-proliferative effect, interacting directly with membrane receptors on tumour cells or by indirect inhibition of 
growth factors, angiogenesis, induction of apoptosis, or their effect on the immune system. The anti-proliferative 
effect of octreotide LAR was demonstrated in the phase III randomised study PROMID, which included 84 treat-
ment-naive patients with disseminated well differentiated NETs of midgut or unknown origin. The anti-tumour effect 
of octreotide LAR was observed irrespective of tumour functional status. Additionally, a retrospective study was 
presented at the ASCO meeting in 2014, showing a therapeutic effect of octreotide LAR of even longer duration 
than in the PROMID study. Authors of the report identified also favourable predictive factors for octreotide LAR 
therapy. The anti-proliferative effect of lanreotide Autogel® was demonstrated in the CLARINET study, which included 
204 patients with non-functioning GEP-NETs, differentiation grade of G1 or G2, proliferation index Ki-67 up to 10%, 
locally inoperable, or metastasised. Results of the study showed decreased relative risk of disease progression 
by 53% in patients with GEP-NETs located in the pancreas, midgut, or of unknown origin.
Key words: neuroendocrine tumours, somatostatin analogues, octreotide LAR, lanreotide Autogel®
Oncol Clin Pract 2015; 11, 5: 272–275
Introduction 
Neuroendocrine tumours (NET) belong to a het-
erogeneous group of rare tumours of endocrine cells 
dispersed throughout the body, forming the so-called 
diffuse endocrine system (DES). These tumours are 
capable of synthesising and secreting bioactive sub-
stances. The NET group is dominated by gastroen-
teropancreatic neuroendocrine tumours/neoplasms 
(GEP-NET/NEN) [1].
Most NETs of the gastrointestinal tract are diag-
nosed at an advanced stage, which impedes radical 
surgery. Somatostatin receptor analogues (SSTA) play 
a major role in the management of non-resectable 
and/or disseminated tumours because almost 80% of 
those overexpress somatostatin receptors (SSTR) [2].
Five types of SSTR were identified, and these 
are expressed in various configurations on tumour 
cells. Overexpression of SSTR2 was found in neuroen-
docrine tumours originating from bronchi, stomach, and 
intestines as well as in schwannoma, medulloblastoma, 
meningioma, neuroblastoma, lymphoma, breast cancer, 
kidney cancer, liver cancer, and lung cancer cells. Sar-
coma and prostatic cancer cells express mostly SSTR1, 
often in coincidence with SSTR5. Non-functioning 
pituitary tumours are characterised by expression 
of SSTR3, whereas gastrointestinal neuroendocrine 
tumours, pheochromocytoma, and meningioma dem-
onstrate expression of SSTR1 and variegated positivity 
for SSTR2 or SSTR5 [3]. Distribution and intensity of 
respective SSTR subtype expression in tumours vary 
markedly between publications, and to a certain extent 
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depend on the applied detection method. Different 
SSTR subtypes may fuse on the cell membrane to form 
a homo- or heterodimer, thus creating a new receptor 
of different characteristics [4].
A study of 81 functioning or non-functioning NETs 
demonstrated expression of SSTR subtype 1, 2, 3, and 
5 in most of them, whereas subtype 4 was identified in 
only single tumours [5]. Somatostatin receptors can 
be found in most well or moderately differentiated 
GEP-NETs. Expression of some SSTR subtypes may 
decrease in the course of the disease, whereas in others 
it may be preserved [6].
Somatostatin (SST) is a cyclic peptide, synthesised 
as a large molecule prohormone (preprosomatostatin) 
in various parts of the gastrointestinal tract or other or-
gans. Prohormone is processed to a 28-aminoacid-long 
peptide (prosomatostatin), and then to 14-aminoac-
id-long somatostatin. The latter exerts its effect via dedi-
cated receptors, inhibiting secretion of gastrointestinal 
or pancreatic hormones. The half-life of SST in blood is 
very short (1–3 minutes), therefore, synthetic forms of 
longer duration are commonly used in oncology, namely 
octreotide and lanreotide as well as their depot forms 
[octreotide long-acting release (LAR) and lanreotide 
Autogel®]. Other synthetic analogues, pasireotide and 
vapreotide, are mainly used by endocrinologists and gas-
troenterologists. Somatostatin binds equally strongly to 
all receptor subtypes but its analogues octreotide and lan-
reotide have a high affinity to SSTR2 and SSTR5, mod-
erately strong affinity to SSTR3, and bind very weakly (if 
ever) to SSTR4 and SSTR1. Pasireotide binds strongly to 
SSTR1, -2, -3, and -5, and vapreotide to SSTR2, -3, and 
-5 but has a moderate affinity to SSTR4 [7].
Somatostatin analogues play a major role in the 
therapy of functioning NETs. Improvement of carci-
noid syndrome was observed under SSTA treatment 
of GEP NETs, with fewer diarrhoeas in 60–70% of 
patients, and lesser rash in 70–80% subjects. Decreased 
synthesis of biologically active substances was found 
in almost 50% of cases and tumour regression in only 
5%, but control of tumour growth could be achieved in 
40–80% of patients. Somatostatin analogues are also 
effective in symptom control of pancreatic NETs, and 
indicated perioperatively in functioning tumours, pro-
tecting the patient from exacerbation of tumour-related 
symptoms. Synthetic SST analogues are generally well 
tolerated, with rare occurrence of adverse events [8, 9].
Binding of SST analogues to specific transmem-
brane receptors in tumour cells decreases secretion 
of hormones and biologically active substances, which 
reduces symptoms but also inhibits disease progression. 
Treatment with SST analogues is currently a standard 
in patients with GEP-NETs, with administration of 
short-acting agents for rapid control of life-threatening 
symptoms caused by functioning tumours [9].
Anti-tumour effect
Given the widespread SSTR expression in various 
tumours, studies on the interaction of SST and its ana-
logues with tumour cells were initiated. The anti-tumour 
effect of SSTA was observed both in vitro and in vivo 
as early as in the 1990s [10–13]. Small prospective or 
retrospective clinical studies gave similar results [14]. 
Recent studies with control groups suggest that SSTA 
may have both cytostatic and cytotoxic effects in some 
tumours. The anti-tumour effect of SSTA varies in dif-
ferent tumour types and receptor subtypes. This effect 
may be due to direct interaction with membrane recep-
tors on tumour cells, activation of proapoptotic cascade 
and anti-mitotic mechanisms, or by indirect inhibition of 
growth factors, angiogenesis, or the influence on the im-
mune system, in particular on lymphocyte proliferation 
or immunoglobulin synthesis. An indirect effect of SSTA 
was observed in an experimental model using a chon-
drosarcoma cell line, which did not express SSTR [15].
Ligand binding to SSTR leads to cell cycle arrest 
by activation of tyrosine kinase, which in turn initiates 
intracellular signalling pathways, and activates cyclin-de-
pendent kinase inhibitors. Subtypes 2 and 3 of SSTR 
seem to be the main mediators of apoptosis in both 
normal and tumour cells. This effect can be explained 
by two mechanisms: direct interaction with SSTR3 and 
indirect action by inhibiting insulin-like growth factor 1 
(IGF1) [16]. Induction of apoptosis occurs due to 
activation of external signalling pathways, leading to 
loss of receptor expression, by TP53-dependent mito-
chondrial pathway related to SSTR3 activation or by 
TP53-independent SSTR2 activation. Interaction with 
SSTR1 and SSTR2 decreases cell migratory/invasive ca-
pacities by inhibiting phosphoinositide 3-kinase (PIK3) 
and/or mitogen-activated protein kinases (MAPK) for 
platelet-derived growth factor (PDGF) as well as by 
activating integrin receptors [17, 18]. Another mode 
of action was proposed recently, with G-protein inde-
pendent inhibition of PI3K upon ligand interaction with 
SSTR2 [19]. These mechanisms inactivate the mamma-
lian target of rapamycin (mTOR) signalling pathway and 
thus inhibit transcription and translation. An important 
anti-proliferative effect of SSTA involves restoration 
of the functional gap junctions between adjacent cells, 
necessary for intercellular signalling [20].
The proapoptotic effect of somatostatin analogues has 
shown clinical benefits. Eriksson et al. observed increased 
apoptosis in tissue samples from GEP-NET in patients 
treated with high doses of SSTA. Additionally, biochemi-
cal response and disease stabilisation was observed in 
12 out of 18 subjects, but there was no correlation between 
apoptosis and decrease of tumour size [21, 22].
The indirect action of SSTA is related to inhibition 
of angiogenesis and counteracting the effect of growth 
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factors. Angiogenesis is crucial for tumour growth, in-
vasion, and metastatic potential; therefore, decreased 
tissue vascularisation upon administration of SST and 
its analogues may inhibit tumour progression. Subtypes 
2 and 5 of SSTR play a role in inhibiting growth hormone 
(GH) secretion from the pituitary gland and the effect 
on the GH/IGF1 feedback loop. By interaction with 
SSTR2 and SSTR3 somatostatin analogues also inhibit 
GH-dependent liver synthesis of IGF1. This occurs due 
to activation of tyrosine phosphatase, dephosphoryla-
tion of protein transducing signals from cell membrane 
to nucleus and phosphorylation of signal transducer 
and activator of transcription 5B protein (STAT5B), 
which in turn inhibits transcription of IGF1 gene 
[23]. Moreover, overexpression of SSTR2 on tumour 
cells causes increased expression of thrombospondin 
1 (TSP1), a potential anti-angiogenic factor in pancre-
atic tumours. Thrombospondin counteracts the proan-
giogenic effect of vascular endothelial growth factor 
(VEGF) [24]. Tumour growth and metastases may also 
be indirectly inhibited by suppression of endothelial pro-
liferation and monocyte migration, with both cell types 
producing normally proangiogenic factors. This effect 
is mediated by ligand interaction with SSTR subtypes 
2, 3, and 5, present on endothelial cells, which leads to 
inhibition of nitric oxide synthase, MAPK3 (ERK1) and 
MAPK1 (ERK2) [25, 26].
Somatostatin analogues also have an immunomodu-
latory effect, regulating mainly NK-cell proliferation 
and immunoglobulin synthesis. It was not definitively 
stated if this phenomenon is of clinical importance, but 
it seems to have an adjuvant effect to the anti-angiogenic 
action of SSTA [27].
Clinical studies
Analogues of SST were initially used for sympto-
matic treatment of functional GEP-NETs, although 
both retrospective and prospective studies in small 
patient groups had revealed the anti-tumour effect of 
these agents.
Proof of anti-proliferative effect of SSTA came from 
the phase III randomised placebo-controlled double 
blind study PROMID, involving 84 treatment-naive 
patients with disseminated well-differentiated NETs of 
midgut or unknown origin (possibly also arising from 
midgut). Patients received 30 mg of octreotide LAR 
every four weeks. Median time to progression (TTP) was 
14.3 months in study group as compared to six months 
in the placebo group. Stable disease was noted after six 
months of treatment in 67% of patients treated with 
octreotide LAR, and in 37% subjects receiving placebo. 
Relative risk of disease progression decreased by 66% 
on treatment. Interestingly, the anti-tumour effect of 
octreotide was independent of tumour functional sta-
tus. One of the secondary end-points of the study was 
overall survival (OS). Seven octreotide-treated patients 
and nine subjects receiving placebo died during the 
study. Treatment reduced, therefore, relative risk of 
death by 19%, but the difference was not statistically 
significant. The most common adverse effects of treat-
ment included gastrointestinal symptoms (transient 
diarrhoea and abdominal pain, most often of mild to 
moderate intensity), cholelithiasis (asymptomatic in 
many patients), and local reactions at the infusion site 
(pain, nodule, or induration). To sum up, the PRO-
MID study demonstrated the anti-proliferative effect 
of octreotide LAR in patients with disseminated NETs 
of midgut origin. Patients included in the study were 
representative for the overall population with this 
diagnosis. The most beneficial effect was stabilisation 
of tumour growth, which contributed to longer time to 
progression. Similar effects were observed irrespective 
of tumour functional status. A more pronounced effect 
was observed in patients after prior resection of primary 
tumour and in patients in whom metastatic tumour 
burden was < 10% of the liver volume [28]. Updated 
results were presented during the 2013 ASCO meeting, 
with a non-significant trend towards better prognosis on 
octreotide LAR treatment, especially in subjects with 
liver metastatic burden < 10% of organ volume. The 
lack of significance may be related to the fact that most 
persons from the placebo arm received octreotide LAR 
when tumour progression was documented [29].
Given the beneficial effects of octreotide LAR study 
in NETs, a retrospective study was performed in order to 
identify predictive factors. The aim of the study was to 
analyse the time to radiological progression of the dis-
ease (TTRP) and potential markers of better response 
to octreotide LAR. The study included 254 patients with 
advanced-stage NET and SSTR expression confirmed 
by scintigraphy. Radiological assessment was performed 
using the RECIST criteria. Both univariate and multi-
variate analyses were performed in order to identify pre-
dictive factors. Mean patient age was 60.5 ± 12.8 years, 
and mean follow-up time was 42 months. Most patients 
(204 persons) had tumours in the small intestine, 22 pa-
tients were diagnosed with pancreatic tumours, 14 had 
lung tumours, 7 persons had rectal tumours, and in 
7 subjects the primary tumour location was unknown. 
Treatment with octreotide LAR was initiated because 
of symptomatic disease in 68% of patients, due to ra-
diological progression in 13% of persons, and following 
publication of the PROMID study results in 29% of 
subjects with non-functioning NETs and stable disease. 
Partial response was observed in 5% of patients. Median 
time to radiological progression was 37 months in the 
entire study population [95% confidence interval (CI): 
32–52 months], with significantly worse outcome in 
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pancreatic NETs, G2 tumours, patients with massive 
liver metastases, or in patients with initial chromogranin 
A (CgA) level of more than ten-fold the upper normal 
limit. In patients with initially stable disease the mean 
time to radiological progression was 53 months. There 
was no correlation between TTRP and patient age, 
mesenteric metastases, desmoplasia, or prior resection 
of primary tumour. Female sex and the presence of 
skeletal metastases had a negative but a non-significant 
impact on TTRP. The authors concluded that the dura-
tion of the anti-proliferative effect of octreotide LAR 
was longer than in the PROMID study. Better response 
to treatment was observed in patients with tumours of 
the small intestine, G1 differentiation grade, small liver 
metastatic burden, low CgA level, or with stable disease 
upon onset of therapy [30].
Another study demonstrating the anti-proliferative 
effect of somatostatin analogues was a multicentre 
double-blind randomised placebo-controlled study 
CLARINET, involving 204 patients with non-func-
tioning gastroenteropancreatic neuroendocrine tu-
mours (GEP-NET) of G1 or G2 differentiation grade, 
proliferation index Ki-67 of 10%, locally unresectable, 
or metastasised. Lanreotide Autogel® contributed to 
a significant decrease of relative risk of disease pro-
gression by 53%. This effect was noted in patients 
with non-functioning G1 or G2 NETs (Ki-67 < 10%) 
of midgut, unknown, or pancreatic origin, irrespective 
of liver metastatic burden (≤ 25% or > 25%). Overall 
survival did not differ significantly between the groups, 
which was probably related to the fact that upon disease 
progression the patients from the placebo arm were 
switched to lanreotide. Treatment was well tolerated, 
and patients’ quality of life was not compromised. The 
most common adverse effects included diarrhoea, re-
ported by 26% of patients treated with lanreotide and 
in 9% of persons in the placebo group [31].
The above-presented data confirm previous observa-
tions of the anti-proliferative effect of SSTA, which are 
capable of inhibiting tumour growth and stabilise the 
disease. These results suggest also a beneficial effect in 
treatment of both hormonally active and non-function-
ing GEP-NETs.
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